Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

Experts give insight on what they are looking forward to in the endometrial cancer space.

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.